» Articles » PMID: 30619505

Mutations Are Frequent in Esophageal Squamous Cell Carcinoma Associated with Chagasic Megaesophagus and Are Associated with a Worse Patient Outcome

Abstract

Background: Chronic diseases such as chagasic megaesophagus (secondary to Chagas' disease) have been suggested as etiological factors for esophageal squamous cell carcinoma; however, the molecular mechanisms involved are poorly understood.

Objective: We analyzed hotspot gene mutations in a series of esophageal squamous cell carcinomas associated or not with chagasic megaesophagus, as well as, in chagasic megaesophagus biopsies. We also checked for correlations between the presence of mutations with patients' clinical and pathological features.

Methods: The study included three different groups of patients: i) 23 patients with chagasic megaesophagus associated with esophageal squamous cell carcinoma (CM/ESCC); ii) 38 patients with esophageal squamous cell carcinoma not associated with chagasic megaesophagus (ESCC); and iii) 28 patients with chagasic megaesophagus without esophageal squamous cell carcinoma (CM). hotspot mutations in exons 9 and 20 were evaluated by PCR followed by direct sequencing technique.

Results: mutations were identified in 21.7% (5 out of 23) of CM/ESCC cases, in 10.5% (4 out of 38) of ESCC and in only 3.6% (1 case out of 28) of CM cases. In the CM/ESCC group, mutations were significantly associated with lower survival (mean 5 months), when compared to wild-type patients (mean 2.0 years). No other significant associations were observed between mutations and patients' clinical features or mutation profile.

Conclusion: This is the first report on the presence of mutations in esophageal cancer associated with chagasic megaesophagus. The detection of mutations in benign chagasic megaesophagus lesions suggests their putative role in esophageal squamous cell carcinoma development and opens new opportunities for targeted-therapies for these diseases.

Citing Articles

Understanding PI3K/Akt/mTOR signaling in squamous cell carcinoma: mutated PIK3CA as an example.

Zheng S, He S, Liang Y, Tan Y, Liu Q, Liu T Mol Biomed. 2024; 5(1):13.

PMID: 38616230 PMC: 11016524. DOI: 10.1186/s43556-024-00176-0.


, Chagas disease and cancer: putting together the pieces of a complex puzzle.

Kaufman C, Farre C, Biscari L, Perez A, Alloatti A Front Cell Dev Biol. 2024; 11:1260423.

PMID: 38188016 PMC: 10768204. DOI: 10.3389/fcell.2023.1260423.


Roles of oncogenes in esophageal squamous cell carcinoma and their therapeutic potentials.

Xiao S, Huang G, Zeng W, Zhou J, Li Y, Fan T Clin Transl Oncol. 2022; 25(3):578-591.

PMID: 36315334 DOI: 10.1007/s12094-022-02981-x.


Integrated cohort of esophageal squamous cell cancer reveals genomic features underlying clinical characteristics.

Li M, Zhang Z, Wang Q, Yi Y, Li B Nat Commun. 2022; 13(1):5268.

PMID: 36071046 PMC: 9452532. DOI: 10.1038/s41467-022-32962-1.


Profile of esophageal squamous cell carcinoma mutations in Brazilian patients.

Munari F, Dos Santos W, Evangelista A, Carvalho A, Pastrez P, Bugatti D Sci Rep. 2021; 11(1):20596.

PMID: 34663841 PMC: 8523676. DOI: 10.1038/s41598-021-00208-7.


References
1.
Luo J, Manning B, Cantley L . Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell. 2003; 4(4):257-62. DOI: 10.1016/s1535-6108(03)00248-4. View

2.
Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S . High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004; 304(5670):554. DOI: 10.1126/science.1096502. View

3.
Velho S, Oliveira C, Ferreira A, Ferreira A, Suriano G, Schwartz Jr S . The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer. 2005; 41(11):1649-54. DOI: 10.1016/j.ejca.2005.04.022. View

4.
Phillips W, Russell S, Ciavarella M, Choong D, Montgomery K, Smith K . Mutation analysis of PIK3CA and PIK3CB in esophageal cancer and Barrett's esophagus. Int J Cancer. 2005; 118(10):2644-6. DOI: 10.1002/ijc.21706. View

5.
Karakas B, Bachman K, Park B . Mutation of the PIK3CA oncogene in human cancers. Br J Cancer. 2006; 94(4):455-9. PMC: 2361173. DOI: 10.1038/sj.bjc.6602970. View